First regulatory filing for vadadustat boosts Akebia Therapeutics

24 July 2019
akebia_big

Shares in Akebia Therapeutics (Nasdaq: AKBA) finished the day around 6% up on Tuesday, after the firm announced the first ever filing for vadadustat, an investigational oral treatment for anemia due to chronic kidney disease (CKD).

The filing was made in Japan by co-development partner Mitsubishi Tanabe Pharma (TYO: 4508). The firms agreed to  work together on the candidate in 2015.

The submission is supported by positive top-line data from Mitsubishi Tanabe’s two Phase III studies in Japanese subjects with anemia due to CKD.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology